Altimmune, Inc. ALT
1.61 USD -0.32 (-16.58%)
At closeNov 12, 2026, 7:59 PM EST
1.63 +0.02 +1.19%
After hours · Nov 12, 7:59 PM ET
1.60 Day range 1.90
1.60 52-week range 6.44
- YTD
- -55.40%
- 1 year
- -61.94%
News
seekingalpha.com Altimmune: Still Too Late And Too Capital-Intensive Altimmune remains a 'Sell' as pemvidutide lacks clear differentiation in the competitive MASH landscape and faces significant funding challenges. ALT's share count has doubled year-over-year, with…
seekingalpha.com Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript
marketbeat.com What Altimmune (ALT) Said on Its Q3 Earnings Call Altimmune NASDAQ: ALT is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration…
benzinga.com Altimmune Q3 2026 Earnings Call Transcript Altimmune (NASDAQ:ALT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Altimmune Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $0 Miss $1.400K Estimate Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 15.38 percent. This is a 28.57 percent increase over losses of $(0.21)…
globenewswire.com Altimmune Announces Third Quarter 2026 Financial Results and Business Update Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2…
benzinga.com Altimmune Publishes IMPACT Phase 2b 48-Week Data In The Lancet Gastroenterology & Hepatology Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profilePublication of…
globenewswire.com Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
benzinga.com Altimmune Reports Phase 2 Results For Pemvidutide In Alcohol Use Disorder, Plans FDA Meeting In December Ahead Of Phase 3 Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD;…
globenewswire.com Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD;…
benzinga.com Altimmune To Present Phase 2 RECLAIM Results For Pemvidutide In Alcohol Use Disorder At AASLD Liver Meeting; FDA End-Of-Phase 2 Meeting Set For December First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)Presentation to take…
globenewswire.com Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026 First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)
globenewswire.com Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist,…
globenewswire.com Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this…
gurufocus.com Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, tod
gurufocus.com TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an inves
gurufocus.com Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
gurufocus.com Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) [url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago(bepiro
globenewswire.com Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026 Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral…
gurufocus.com SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
prnewswire.com Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets MCLEAN, Va., Oct. 14, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, aircraft surveillance, and positioning, navigation, and timing (PNT)…
marketbeat.com Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic…
gurufocus.com AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw- benzinga.com Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17 Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.
globenewswire.com Altimmune to Participate in Stifel Cardiometabolic Forum GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today…
gurufocus.com AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 55.56 percent increase over losses of $(0.27) per…
benzinga.com Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…- benzinga.com Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met,…
- benzinga.com Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10 Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperform rating and announces Price Target of $10.
benzinga.com Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis. The data are being presented today and Friday in poster sessions, including a late-breaking poster presentation, at the European Association for the Study of the Liver (EASL) Congress 2026 in…- benzinga.com HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.
- benzinga.com Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11 Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $14 to $11.
- benzinga.com Altimmune Q1 2026 Earnings Call: Complete Transcript
- benzinga.com Altimmune To Present Analyses Of Data From IMPACT Phase 2b Clinical Trial In Metabolic Dysfunction-Associated Steatohepatitis At EASL Congress 2026 Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "Best of EASL 2026" by EASLOral presentation will highlight further the 48-week IMPACT efficacy and…
- benzinga.com Altimmune Q1 EPS $(0.18) Beats $(0.25) Estimate. Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.25) by 28 percent. This is a 30.77 percent increase over losses of $(0.26) per…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Why Is Altimmune Stock Falling Today? Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-stage trials.
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Altimmune Announces Public Offering; Quantity And Termination Date Not Disclosed Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), as well as for working capital and…
benzinga.com HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.- benzinga.com B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13 B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $18 to $13.
benzinga.com Altimmune: Q4 Earnings Insights